Effectiveness of quinolone antibiotics in modulating the effects of antifungal drugs

Antimicrobial Agents and Chemotherapy

Volumn 41, Issue 11, 1997, Pages 2518-2521

  Sugar, Alan M ^a   Liu, Xiu Ping ^a   Chen, Rong Jin ^a  

^a BOSTON MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; ANTIFUNGAL AGENT; CIPROFLOXACIN; DNA TOPOISOMERASE (ATP HYDROLYSING); FLUCONAZOLE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; TROVAFLOXACIN;

ANIMAL CELL; ANIMAL TISSUE; ANTIBIOTIC THERAPY; ANTIFUNGAL ACTIVITY; ARTICLE; BACTERIAL COUNT; CANCER SURVIVAL; CANDIDA ALBICANS; CONTROLLED STUDY; DRUG MECHANISM; ENZYME INHIBITION; INTRAPERITONEAL DRUG ADMINISTRATION; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL;

EID: 0030667660     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/aac.41.11.2518     Document Type: Article

References (13)

1. Dykstra, C. C., D. R. McClernon, L. P. Elwell, and R. R. Tidwell. 1994. Selective inhibition of topoisomerases from Pneumocystis carinii compared with that of topoisomerases from mammalian cells. Antimicrob. Agents Chemother. 38:1890-1898.
2. Fostel, J., D. Montgomery, and P. Lartey. 1996. Comparison of responses of DNA topoisomerase I from Candida albicans and human cells to four new agents which stimulate topoisomerase-dependent DNA nicking. FEMS Microbiol. Lett. 138:105-111.
3. Fu, K., N. Hetzel, F. Gregory, and P. Hung. 1987. Therapeutic efficacy of cefpiramide-ciprofloxacin combination in experimental pseudomonas infections in neutropenic mice. J. Antimicrob. Chemother. 20:541-546.
4. Gellert, M., K. Mizuuchi, M. H. O'Dea, T. Itoh, and J.-I. Tomizawa. 1977. Nalidixic acid resistance: a second genetic character involved in DNA gyrase activity. Proc. Natl. Acad. Sci. USA 74:4772-4776.
5. Marklein, G. 1996. Quinolones in everyday clinical practice: respiratory tract infections and nosocomial pneumonia. Chemotherapy 42(Suppl. 1):33-42.
6. Nakajima, R., A. Kitamura, K. Someya, M. Tanaka, and K. Sato. 1995. In vitro and in vivo antifungal activities of DU-6859a, a fluoroquinolone, in combination with amphotericin B and fluconazole against pathogenic fungi. Antimicrob. Agents Chemother. 39:1517-1521.
7. National Committee for Clinical Laboratory Standards. 1992. Reference method for broth dilution antifungal susceptibility testing for yeasts. Proposed standard. Document M27-P. National Committee for Clinical Laboratory Standards, Villanova, Pa.
8. Shen, L. L., and J. M. Fostel. 1994. DNA topoisomerase inhibitors as antifungal agents. Adv. Pharmacol. 29B:227-244.
9. Sugar, A. M., C. A. Hitchcock, P. F. Troke, and M. Picard. 1995. Combination therapy of murine invasive candidiasis with fluconazole and amphotericin B. Antimicrob. Agents Chemother. 39:598-601.
10. Sugar, A. M., and X.-P. Liu. 1995. Comparison of three methods of antifungal susceptibility testing with the proposed NCCLS standard broth macrodilution assay: lack of effect of phenol red. Diagn. Microbiol. Infect. Dis. 21:129-133.
11. Sugar, A. M., M. Salibian, and L. Z. Goldani. 1994. Saperconazole therapy of murine disseminated candidiasis: efficacy and interactions with amphotericin B. Antimicrob. Agents Chemother. 38:371-373.
12. Sugino, A., C. L. Peebles, K. N. Kreuzer, and N. R. Cozzarelli. 1977. Mechanism of action of nalidixic acid: purification of Escherichia coli nalA gene product and its relationship to DNA gyrase and a novel nicking-closing enzyme. Proc. Natl. Acad. Sci. USA 74:4767-4771.
13. Thadepalli, H., U. Reddy, S. Chuah, F. Thadepalli, C. Malilay, R. Polzer, N. Hanna, A. Esfandiari, P. Brown, and S. Gollapudi. 1997. In vivo efficacy of trovafloxacin (CP-99,217), a new quinolone, in experimental intra-abdominal abscesses caused by Bacteroides fragilis and Escherichia coli. Antimicrob. Agents Chemother. 41:583-586.